Findings

What do systematic reviews say?

4,919 questions · 13,869 findings · 2,177 reviews · Headline outcomes only

Sort:Best matchNewestHighest certainty Download CSV

No studies found 13,869 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Omega‐3 vs placebo

Frequency of hospitalization · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for sickle cell disease 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Omega‐3 vs placebo

Frequency of sickle cell‐related complications · sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for sickle cell disease 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Vitamin C 1400 mg plus vitamin E 800 mg vs placebo

Frequency of hospitalization · adults with sickle cell disease (adults with homozygous SCA or sickle beta 0 thalassaemia SCD)

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for sickle cell disease 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Zinc vs placebo

Severity of pain · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Antioxidant supplementation for sickle cell disease 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Escitalopram vs placebo

Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Escitalopram vs placebo

Quality of life at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

Health‐related quality of life · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

Disease progression · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Double‐dose adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation

Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin

Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human adenovirus‐p53 and hydroxycamptothecin (rAd‐p53/HCT) vs hydroxycamptothecin

Health‐related quality of life · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs chemoembolisation

Overall survival · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs chemoembolisation

Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs chemoembolisation

Health‐related quality of life · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs chemoembolisation

Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

E1B‐deleted (dl1520) adenovirus vs percutaneous alcohol injection

Overall survival · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

E1B‐deleted (dl1520) adenovirus vs percutaneous alcohol injection

Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

E1B‐deleted (dl1520) adenovirus vs percutaneous alcohol injection

Health‐related quality of life · participants with unresectable hepatocellular carcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Gene therapy for people with hepatocellular carcinoma 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found